Evidence map›Paper›PMID 33674381›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2021

Computational studies of anaplastic lymphoma kinase mutations reveal common mechanisms of oncogenic activation.

Keshav Patil, Earl Joseph Jordan, Jin H Park, Krishna Suresh, Courtney M Smith, Abigail A Lemmon, Yaël P Mossé, Mark A Lemmon, Ravi Radhakrishnan

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Machine Learning in Drug Discovery: A Review.Artificial intelligence review · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Keshav PatilDepartment of Chemical and Biomolecular Engineering, University of Pennsylvania, Philadelphia, PA 19104-6315.ORCID 0000-0003-1722-9314
Earl Joseph JordanGraduate Group in Biochemistry and Molecular Biology, University of Pennsylvania, Philadelphia PA 19104-6073.
Jin H ParkGraduate Group in Biochemistry and Molecular Biology, University of Pennsylvania, Philadelphia PA 19104-6073.ORCID 0000-0001-7017-4979
Krishna SureshDepartment of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104-6321.ORCID 0000-0003-1274-3189
Courtney M SmithDepartment of Pharmacology, Yale University, New Haven, CT 06520.ORCID 0000-0002-4248-1987
Abigail A LemmonDepartment of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA 19104-6073.ORCID 0000-0001-6798-9384
Yaël P MosséChildren's Hospital of Philadelphia, Philadelphia, PA 19104.
Mark A LemmonGraduate Group in Biochemistry and Molecular Biology, University of Pennsylvania, Philadelphia PA 19104-6073; mark.lemmon@yale.edu rradhak@seas.upenn.edu.ORCID 0000-0002-3379-5319
Ravi RadhakrishnanDepartment of Chemical and Biomolecular Engineering, University of Pennsylvania, Philadelphia, PA 19104-6315; mark.lemmon@yale.edu rradhak@seas.upenn.edu.ORCID 0000-0003-0686-2851
University of Pennsylvania · USYale Cancer Center · USChildren's Hospital of Philadelphia · US

Funding

Understanding Signaling by Non-Canonical Receptor Tyrosine KinasesR35GM122485 · NIGMS · YALE UNIVERSITY · PI Mark A Lemmon · 2017 to 2026
$7.9M
Multiscale Modeling to Optimize Inhibition of Oncogenic ERK Pathway SignalingR01CA244660 · NCI · YALE UNIVERSITY · PI HLAVACEK, WILLIAM S, KHOLODENKO, BORIS N · 2020 to 2024
$3.4M
A plasticity and reprogramming paradigm for therapy resistance at the single cell levelU01CA227550 · NCI · UNIVERSITY OF PENNSYLVANIA · PI RADHAKRISHNAN, RAVI, RAJ, ARJUN · 2018 to 2022
$3.3M
NCI NIH HHS R01 CA244660NCI NIH HHS U01 CA227550NIGMS NIH HHS R35 GM122485
6 · The paper itself

Abstract

Kinases play important roles in diverse cellular processes, including signaling, differentiation, proliferation, and metabolism. They are frequently mutated in cancer and are the targets of a large number of specific inhibitors. Surveys of cancer genome atlases reveal that kinase domains, which consist of 300 amino acids, can harbor numerous (150 to 200) single-point mutations across different patients in the same disease. This preponderance of mutations-some activating, some silent-in a known target protein make clinical decisions for enrolling patients in drug trials challenging since the relevance of the target and its drug sensitivity often depend on the mutational status in a given patient. We show through computational studies using molecular dynamics (MD) as well as enhanced sampling simulations that the experimentally determined activation status of a mutated kinase can be predicted effectively by identifying a hydrogen bonding fingerprint in the activation loop and the αC-helix regions, despite the fact that mutations in cancer patients occur throughout the kinase domain. In our study, we find that the predictive power of MD is superior to a purely data-driven machine learning model involving biochemical features that we implemented, even though MD utilized far fewer features (in fact, just one) in an unsupervised setting. Moreover, the MD results provide key insights into convergent mechanisms of activation, primarily involving differential stabilization of a hydrogen bond network that engages residues of the activation loop and αC-helix in the active-like conformation (in >70% of the mutations studied, regardless of the location of the mutation).

Indexed as

Machine LearningMolecular Dynamics SimulationMutationAnaplastic Lymphoma KinaseEnzyme ActivationHumansProtein Conformation, alpha-HelicalALK protein, humanAnaplastic Lymphoma Kinasedriver mutationsfocus formation assaykinase activationmachine learningmolecular dynamics

Identifiers

PMID33674381
PMCPMC7958353
OpenAlexW3134826310

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.